Evidence map›Paper›PMID 29877179›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2018

Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.

Pierre I Karakiewicz, Emanuele Zaffuto, Anil Kapoor, Naveen S Basappa, Georg A Bjarnason, Normand Blais, Rodney H Breau, Christina Canil, Darrel Drachenberg, Sebastien J Hotte and 16 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2019
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 9 institutions in 1 country.

Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada.
Emanuele ZaffutoCancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada.
Anil KapoorDivision of Urology, McMaster University, Hamilton, ON, Canada.
Naveen S BasappaDepartment of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada.
Georg A BjarnasonDivision of Medical Oncology/Hematology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Normand BlaisDivision of Medical Oncology/Hematology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Rodney H BreauClinical Epidemiology Program and Division of Urology, The Ottawa Hospital Research Institute and University of Ottawa Ottawa, ON, Canada.
Christina CanilDivision of Medical Oncology, The Ottawa Hospital Cancer Centre and the University of Ottawa, Ottawa, ON, Canada.
Darrel DrachenbergSection of Urology, University of Manitoba, Winnipeg, MB, Canada.
Sebastien J HotteJuravinski Cancer and McMaster University, Hamilton, ON, Canada.
Claudio JeldresCentre hospitalier de l'Université de Sherbrooke, Sherbrooke, QC, Canada.
Michael A S JewettDepartments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Wassim KassoufDivision of Urology, McGill University, Montreal, QC, Canada.
Christian KollmannsbergerDivision of Medical Oncology, British Columbia Cancer Agency-Vancouver Cancer Centre, and the University of British Columbia, Vancouver, BC, Canada.
Luke T LavalléeClinical Epidemiology Program and Division of Urology, The Ottawa Hospital Research Institute and University of Ottawa Ottawa, ON, Canada.
Ranjena MaloniDepartments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Francois PatenaudeDepartment of Medicine, Hematology Service and Department of Oncology, Sir Mortimer B. Davis Jewish General Hospital and McGill University, Montreal, QC, Canada.
Frédéric PouliotDivision of Urology, Department of Surgery, Université Laval, Quebec, QC, Canada.
M Neil ReaumeDivision of Medical Oncology, The Ottawa Hospital Cancer Centre and the University of Ottawa, Ottawa, ON, Canada.
Robert SabbaghCentre hospitalier de l'Université de Sherbrooke, Sherbrooke, QC, Canada.
Bobby ShayeganDivision of Urology, McMaster University, Hamilton, ON, Canada.
Alan SoDepartment of Urologic Sciences, The University of British Columbia, Vancouver, BC, Canada.
Denis SoulièresDivision of Medical Oncology/Hematology Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Simon TanguayDivision of Urology, McGill University, Montreal, QC, Canada.
Lori WoodDepartment of Medicine and Urology, Dalhousie University, Halifax, NS, Canada.
Marco BandiniCancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada.
Centre Hospitalier de l’Université de Montréal · CAMcGill University · CAMcGill University Health Centre · CAMcMaster University · CADalhousie University · CAUniversité de Montréal · CAUniversity of Alberta · CAUniversity of British Columbia · CAUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe Kidney Cancer Research Network of Canada (KCRNC) collaborated to prepare this consensus statement about the use of target agents as adjuvant therapy in patients with non-metastatic renal cell carcinoma (nmRCC) after nephrectomy. We reviewed the published data and performed a meta-analysis of studies that focused on vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs).

methodsA systematic literature search identified seven trials on adjuvant target therapy in nmRCC. Three trials, the ASSURE, S-TRAC, and PROTECT, focused on VEGFR TKIs and represented the focus of the study, including a meta-analysis combining their data on disease-free survival (DFS) and overall survival (OS).

resultsThe ASSURE trial showed no DFS or OS benefit of TKIs over placebo after one year of adjuvant sorafenib or sunitinib. In contrast, the S-TRAC trial showed improved DFS after one year of adjuvant sunitinib using central review process, but not using investigator review process. No OS benefit was recorded in either study. Recently, the PROTECT trial also showed no DFS or OS benefit when one year of adjuvant pazopanib was compared to placebo. Meta-analyses of the pooled DFS and OS estimates from all three trials resulted in DFS and OS hazard ratios of 0.87 (95% confidence interval [CI] 0.73-1.04) and 1.04 (95% CI 0.89-1.22), respectively.

conclusionsData from three available clinical trials of adjuvant VEGFR TKIs vs. placebo do not currently support the use of adjuvant TKI therapy as standard of care after nephrectomy for nmRCC. At this time, adjuvant TKI-based adjuvant therapy is not recommended for routine use after nephrectomy for high-risk nmRCC, but highly motivated patients may benefit from a discussion with their oncologist regarding the risks and benefits of adjuvant TKI.

Identifiers

PMID29877179
PMCPMC5994982
OpenAlexW2792512381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.